The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in the Rocky Mountain region - an area with a population of approximately eight million people. The goals are to reduce the cancer burden by: 1) conducting coordinated and interdisciplinary basic, clinical, translation, prevention and control, population, and educational research, 2) providing citizens of Colorado and the Rocky Mountain region with state-of-the art programs in cancer research, therapy, early detection, prevention and control, and 3) providing cancer education at all levels from students to the public sector. There are 271 full and 110 associate members who participate in one or more of the UCCC's eight programs including Cancer Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Carcinogenesis and Chemoprevention, and Clinical and Community Cancer Prevention and Control. Over the past five years, the NCI sponsored research portfolio has nearly doubled from $21 million to $39.7 million, excluding the CCSG. This was accomplished largely through the successful funding of major new collaborative NCI grants and contracts totaling more than $7 million annually and through the recruitment of 100 new members who hold more than $14 million in NCI grant support. Over the past five years, the number of subjects accrued to clinical trials and the number of outpatient visits have also doubled. The Cancer Center is a """"""""matrix"""""""" Cancer Center within the University of Colorado Denver and Health Sciences Center and we are applying as a consortium with members from the University of Colorado at Boulder campus, the AMC Cancer Research Center, the National Jewish Medical and Research Center, and the Colorado State University campuses. These consortium members strengthen and broaden cancer research activities. Member research is supported by 15 shared core resources, of which the Informatics shared resource and the Structural Biology shared resource are new. Major new services and equipment were added to most of the shared resources. Center members also benefit from the Development activities of the Cancer Center that bring new recruitments, pilot projects and shared facilities. Planning and evaluation efforts have allowed our on-going move to the new Fitzsimons campus to provide state-of-the art facilities and increased collaborations. The completion of the new campus will allow continued growth over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-21S3
Application #
7684299
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-04-04
Project End
2011-01-31
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
21
Fiscal Year
2008
Total Cost
$85,992
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464
Elder, Alan M; Tamburini, Beth A J; Crump, Lyndsey S et al. (2018) Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer Res 78:6473-6485

Showing the most recent 10 out of 1634 publications